pharmaphorum
MAY 3, 2022
Israeli cancer diagnosis startup Imagene AI has raised $21.5 million in first-round financing for its cancer diagnosis platform based digitised imaging of biopsy samples. The Series A – led by Oracle co-founder Larry Ellison and fellow investors Dr David Ahus and Zebra Medical Vision founder Eyal Gura – includes $3 million in seed funding from venture capital firm Blumberg Capital.
Board Vitals - Pharmacist
MAY 3, 2022
Happy Nurses Week 2022! During this week, which occurs annually on May 6-12, we take the time to recognize nurses and the impact they’ve made on the patient population. Many businesses offer discounts and freebies to show their support for nurses around the country. Here are some of the top Nurses Week promotions for 2022. . The below information was collected for Nurses Week 2022 and may include the previous year’s offers as some companies have not announced their offers as of publishing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MAY 3, 2022
Alain Labrique, PhD, professor and associate chair of research at Johns Hopkins Bloomberg School of Public Health (JHSPH) and chair of the World Health Organization (WHO) digital health guidelines development group discusses with us the ongoing research study, National Pandemic Pulse, he and his colleagues are performing in the US. Using comprehensive, repeat surveys deployed across the US population, Labrique and fellow researchers at JHSPH are measuring disparities and inequities due to COVID
Compounding Pharmacy of America
MAY 3, 2022
When a loved one is in hospice care, family members and caregivers need to make difficult, often emotional decisions. This often comes after an already-long road of supporting your loved one as they battle disease or through declining health. As a caregiver, you need to make sure your loved one is comfortable and getting everything […]. The post Loved Ones in Hospice Benefit From Compounding Meds appeared first on The Compounding Pharmacy of America.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
MAY 3, 2022
Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai. The new drug – Quviviq (daridorexant) – has been approved by the European Commission for adults who have been suffering insomnia for at least three months and are experiencing “considerable impact” on daytime functioning, according to the Swiss pharma company.
Roots Analysis
MAY 3, 2022
Blue ocean strategy, a concept first introduced in 2004, by W Chan Kim, and Renee Mauborgne in their bestselling book of the same name, talks about how to achieve a breakthrough in a highly saturated market by focusing on creating a new uncontested market. Blue ocean strategy is a systematic approach that helps emerging service providers to create a new demand, rather than competing for an already existing demand.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Outsourcing Pharma
MAY 3, 2022
ObvioHealth and 1nHealth have joined to launch an initiative aimed at helping clinical trials avoid being shut down by smoothing the change to decentralized.
pharmaphorum
MAY 3, 2022
Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics’ TriNKET platform to find therapies for cancer and inflammatory diseases. The deal initially focuses on preclinical-stage immunotherapy DF-7001 which targets 5T4, a protein found on cancer cells and stromal cells that is though to drive growth of various solid tumours, including non-small-cell lung cancer (NSCLC), breast cancer, pancreatic cancer a
Pharma Times
MAY 3, 2022
Byondis and Medac have entered into a license and collaboration agreement for form of targeted chemotherapy
pharmaphorum
MAY 3, 2022
With TCEs being studied in both hematological and solid tumors (39 and 34 trials respectively), there are now more than one hundred projects in the preclinical stage. Early clinical outcomes and novel TCE design modifications have fueled the development and clinical advancement of over 65 bispecific T-cell engagers (TCEs), which are presently in Phase I and Phase II investigations since the Cell Engager Series began.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
MAY 3, 2022
The EC’s decision on the insomnia treatment was supported by phase 3 trial results
pharmaphorum
MAY 3, 2022
Biogen has announced a major revamp of its business that will see chief executive Michel Vounatsos depart the company, and all commercial activities related to troubled Alzheimer’s therapy Aduhelm cease. Michel Vounatsos. The headline news in the company’s first-quarter results statement (PDF) was Vounatsos’ departure, although he will remain at the helm of Biogen until a new CEO is found to help oversee a revitalisation of the company.
Outsourcing Pharma
MAY 3, 2022
Introduced by two Republican Congressmen, the American Made Medicine Act is intended to boost domestic drug manufacturing and create jobs in the sector.
Expert insights. Personalized for you.
137 
Let's personalize your content